tech transfer

CeeD is committed to transform its research discoveries into innovative products to improve daily life of patients and, at the end, remain financially independent. For this purpose, the laboratory encourages patenting and stimulates entrepreneurship within its teams.

Discover our spin-off Ilonov:

Founded in December 2020 and based on the work of the Dr. Bouzakri (Bouzakri et al. Diabetes 2003 and 2011), Ilonov is an early-stage biotech company dedicated to developing first-in-class biologics against chronic metabolic diseases such as diabetes, harvesting the potential of the muscle secretome to regulate metabolism, an innovative and unexplored approach.

This biotherapy specifically preserves & stimulates pancreatic beta cell function by restoring the integrity of the extracellular matrix of the islet niche. Discovered in human muscle post-exercise, this asset, ILV-001 has already proven safety & efficacy in preclinical T1D (Type 1 Diabetes) & T2D (Type 2 Diabetes) models in vivo.

Ilonov is currently developing two treatments:

#1

A fast-to-market adjuvant to enhance islet function ex vivo, dedicated to T1D patients with unstable insuline secretion. This innovation is a unique combination of pre- transplant treatments based on ILV-001, ensuring better islet survival, limiting graft rejection and enhancing its potency in the long term.

#2

A biologic drug for T1 and T2 patients’ treatment, restoring insulin sensitivity of peripheral tissues and preventing comorbidities.

Over time, our main objective is to become a pioneer in the treatment of type 1 and type 2 diabetes by restoring patient’s quality of life, preventing disease progression and eliminating diabetes’ complications like stroke, renal failure and so on.

The founded team is composed of:

Dr Anastasia GRABARZ, CEO
Dr Karim BOUZAKRI, CSO and President
Pr Michel PINGET, CMO

Since its creation, Ilonov has been supported & awarded:

Winner of the iLab, bpi innovation competition for early stage companies (pre-seed funding of 1.2 M€)
Winner of the bpi Deep Tech Emergence Grant
Laureate of several Region Grand Est grants
Selected for the 2022 Galien Therapeutic Award
Part of the NEXT Biotech Booster Program 2022
Part of the 2023 Neighborhood Program from Voisin Consulting, a prestigious life science supporting firm